A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

Summary

A multicenter, randomized, placebo-controlled clinical trial, double-blind, parallel-group

Timeline

Start

2023-03-17

Primary completion

2024-09-30

Completion

2024-09-30

Outcome

Met primary endpoint

paper At week 24, the placebo-adjusted mean change in HbA1c from baseline in the enavogliflozin group was -0.9% (P<0.001). PMID 41397686 ↗

Publications

• Hong JH, Min KW, Lee CB, Chamnan P, Sirirak T, Sony K, Sattanon S, Kim HJ, Kim SY, Kim Y, Heo JA, Cho JM, Nah JJ, Park MH, Kim JH. Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs. Diabetes Metab J. 2025 Dec 15. doi: 10.4093/dmj.2025.0477. Online ahead of print.

Drugs

Indications